| 1.77 -2.46 (-58.16%) | 03-31 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 5.68  |
1-year : | 8.23 |
| Resists | First : | 4.86 |
Second : | 7.05 |
| Pivot price | 4.83 |
|||
| Supports | First : | 1.33 |
Second : | 1.1 |
| MAs | MA(5) : | 4.05 |
MA(20) : | 5.11 |
| MA(100) : | 5.55 |
MA(250) : | 3.45  |
|
| MACD | MACD : | -0.7 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 4.9 |
D(3) : | 8.3 |
| RSI | RSI(14): 18.3 |
|||
| 52-week | High : | 7.8 | Low : | 0.87 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ PEPG ] has closed below the lower bollinger band by 28.6%. If price is in a downtrend band; this downward trend might continue. However a short term pullback inside the band is likely. Bollinger Bands are 102.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.08 - 2.1 | 2.1 - 2.11 |
| Low: | 1.31 - 1.32 | 1.32 - 1.33 |
| Close: | 1.72 - 1.74 | 1.74 - 1.75 |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Tue, 31 Mar 2026
PepGen (NASDAQ:PEPG) Price Target Lowered to $5.00 at Wedbush - MarketBeat
Tue, 31 Mar 2026
PepGen’s Stock Plummets Amid FDA Trial Hold and Market Reaction - StocksToTrade
Tue, 31 Mar 2026
Why Is PepGen Stock Sinking Tuesday? - PepGen (NASDAQ:PEPG) - Benzinga
Tue, 31 Mar 2026
PepGen posts trial data for muscle disorder drug (PEPG:NASDAQ) - Seeking Alpha
Mon, 30 Mar 2026
PepGen reports favorable safety and splicing trends for 5 mg/kg cohort, on track for 10 mg/kg readout - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 69 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 92.6 (%) |
| Shares Short | 3,350 (K) |
| Shares Short P.Month | 2,850 (K) |
| EPS | -2.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.14 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -36.1 % |
| Return on Equity (ttm) | -67.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -0.82 |
| PEG Ratio | 0 |
| Price to Book value | 0.81 |
| Price to Sales | 0 |
| Price to Cash Flow | -1.47 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|